Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Source ↗
👁 2
💬 0
The post Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? appeared first on 24/7 Wall St..
Moderna (MRNA) jumps 9% today to $57, extending a +94% YTD rally—the best performer in the vaccine cohort, crushing Pfizer (PFE) at +4% and Novavax (NVAX) at +41%.
Moderna's leadership restructuring signals operational read
Moderna (MRNA) jumps 9% today to $57, extending a +94% YTD rally—the best performer in the vaccine cohort, crushing Pfizer (PFE) at +4% and Novavax (NVAX) at +41%.
Moderna's leadership restructuring signals operational read
Comments (0)